Inspyr Therapeutics Initiates Mipsagargin with Nexavar Combination Therapy Programs for Liver Cancer
January 03, 2017 at 12:00 pm
Share
Inspyr Therapeutics announced the initiation of development programs focused on Mipsagargin combination therapies. To evaluate the potential of Mipsagargin in combination with Nexavar®, Inspyr plans to conduct a preclinical study in liver PDX tumor models that express PSMA, the target of Mipsagargin. The tumor models selected express different levels of PSMA, including one that is resistant to Nexavar®. The Company expects to share initial results of this study in the second quarter of 2017. Concurrently, the Company is finalizing the design of a clinical study to examine the potential benefits of Mipsagargin in combination with Nexavar® in patients with advanced hepatocellular carcinoma (HCC), or liver cancer.
Rebus Holdings, Inc. is a pharmaceutical company. The Company is focused on the research and development of targeted precision therapeutics for the treatment of cancer. The Company utilizes its proprietary delivery technology to enhance immuno-modulation for developing therapeutic outcomes. Its immune-oncology lead asset, RT-AR001, is an adenosine A2A receptor antagonist, is differentiated by its intratumoral delivery of nano- or microparticle formulations that allow for better tumor infiltration. Its patented portfolio of adenosine receptor antagonists provides treatment based on the specific adenosine targets found in each type of cancer. The adenosine receptor modulators include A2A, A2B and dual A2A/A2B antagonists, that have broad development applicability, including indications within immuno-oncology. It is also engaged in the manufacturing of platform delivery systems for nano- or microparticle formulations that are used in toxicology studies.